COVID-MATCH65-A prospectively derived clinical decision rule for severe acute respiratory syndrome coronavirus 2.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
08
2020
accepted:
20
11
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
22
12
2020
Statut:
epublish
Résumé
We report on the key clinical predictors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and present a clinical decision rule that can risk stratify patients for COVID-19. A prospective cohort of patients assessed for COVID-19 at a screening clinic in Melbourne, Australia. The primary outcome was a positive COVID-19 test from nasopharyngeal swab. A backwards stepwise logistic regression was used to derive a model of clinical variables predictive of a positive COVID-19 test. Internal validation of the final model was performed using bootstrapped samples and the model scoring derived from the coefficients, with modelling performed for increasing prevalence. Of 4226 patients with suspected COVID-19 who were assessed, 2976 patients underwent SARS-CoV-2 testing (n = 108 SARS-CoV-2 positive) and were used to determine factors associated with a positive COVID-19 test. The 7 features associated with a positive COVID-19 test on multivariable analysis were: COVID-19 patient exposure or international travel, Myalgia/malaise, Anosmia or ageusia, Temperature, Coryza/sore throat, Hypoxia-oxygen saturation < 97%, 65 years or older-summarized in the mnemonic COVID-MATCH65. Internal validation showed an AUC of 0.836. A cut-off of ≥ 1.5 points was associated with a 92.6% sensitivity and 99.5% negative predictive value (NPV) for COVID-19. From the largest prospective outpatient cohort of suspected COVID-19 we define the clinical factors predictive of a positive SARS-CoV-2 test. The subsequent clinical decision rule, COVID-MATCH65, has a high sensitivity and NPV for SARS-CoV-2 and can be employed in the pandemic, adjusted for disease prevalence, to aid COVID-19 risk-assessment and vital testing resource allocation.
Identifiants
pubmed: 33296409
doi: 10.1371/journal.pone.0243414
pii: PONE-D-20-24559
pmc: PMC7725390
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0243414Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2307-2309
pubmed: 32463454
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):166-170
pubmed: 32053579
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Ann Transl Med. 2020 Jul;8(14):859
pubmed: 32793703
Infect Control Hosp Epidemiol. 2020 Aug;41(8):968-969
pubmed: 32423519
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Ann Intern Med. 2020 Jun 2;172(11):726-734
pubmed: 32282894